NuoCheng Jianhua Pharmaceutical Co., Ltd. Announcement on Holding the 2025 Annual Performance Briefing

Log in to the Sina Finance app and search for 【information disclosure】 to view evaluation tiers

A-share code: 688428 A-share stock abbreviation: Innovent Biologics (No, sorry, must match? ) Announcement No.: 2026-002

Hong Kong stock code: 09969 Hong Kong stock abbreviation: Innovent Biologics

Innovent Biologics (China) Ltd.

Notice of the Convening of the 2025 Annual Results Briefing

The board of directors of the Company and all directors hereby confirm that this announcement contains no false statements, misleading representations or material omissions, and undertake legal responsibility for the truthfulness, accuracy and completeness of the contents of this announcement.

Key Matters:

● Meeting time: 11:00-12:00 a.m. on March 26, 2026 (Thursday)

● Meeting location: Shanghai Stock Exchange SSE Roadshow Center (website:

● Meeting method: Online interaction via the SSE Roadshow Center

● Investors may submit questions by logging in to the homepage of the SSE Roadshow Center and clicking the “Question Pre-collection” section between 16:00 on March 19, 2026 (Thursday) and 3:25, 2026 (Wednesday) or by emailing the company at IR@innocarepharma.com. The Company will respond at the briefing to questions that investors generally care about

Innovent Biologics (China) Ltd. (hereinafter referred to as the “Company”) will release the Company’s 2025 annual report on March 26, 2026. To help the broad base of investors gain a more comprehensive and in-depth understanding of the Company’s 2025 annual operating results and financial position, the Company plans to hold the 2025 annual results briefing from 11:00-12:00 a.m. on March 26, 2026 (Thursday), and exchange views on matters of concern to investors.

I. Type of Briefing

This investor briefing will be held in the form of online interaction. The Company will interact and communicate with investors regarding the specific circumstances of the 2025 annual operating results and financial indicators, and within the scope permitted by information disclosure rules, will respond to questions that investors generally care about.

II. Time and Location of the Briefing

(I) Meeting time: 11:00-12:00 a.m. on March 26, 2026 (Thursday)

(II) Meeting location: Shanghai Stock Exchange SSE Roadshow Center (website:

(III) Meeting method: Online interaction via the SSE Roadshow Center

III. Participants

Chairman of the Board and Chief Executive Officer: Dr. Jisong Cui (Cui Jisong)

Independent Non-executive Director: Ms. Hulan Hu

Chief Financial Officer: Mr. Xin Fu

Domestic representative for information disclosure: Ms. Bei Yuan

(In the event of special circumstances, the participants may be adjusted)

IV. Investor Participation Methods

(I) Investors may, between 11:00-12:00 a.m. on March 26, 2026 (Thursday), log in to the SSE Roadshow Center via the Internet (

(II) Investors may, before 16:00 on March 25, 2026 (Wednesday), log in to the homepage of the SSE Roadshow Center, click the “Question Pre-collection” section (

V. Contact Person and Consultation Methods

Contact person: Domestic Securities Affairs Department

Telephone: 010-66609913

Email: IR@innocarepharma.com

VI. Other Matters

After this investor briefing is held, investors may do so via the SSE Roadshow Center (

This announcement is hereby issued.

Board of Directors of Innovent Biologics (China) Ltd.

March 18, 2026

Endless information and precise insights—right on the Sina Finance app